The Fanconi Anaemia Pathway: Interstrand Crosslink Repair
The Fanconi anaemia pathway is a network of more than twenty genes that together repair DNA interstrand crosslinks, lesions that covalently tie the two strands together and block both replication and transcription. Several of its downstream members are familiar cancer-predisposition genes, including BRCA1, BRCA2 and PALB2.
Quick Answer
The Fanconi anaemia pathway is a network of more than twenty genes that together repair DNA interstrand crosslinks, lesions that covalently tie the two strands together and block both replication and transcription. Several of its downstream members are familiar cancer-predisposition genes, including BRCA1, BRCA2 and PALB2.
Part of a topic cluster
DNA Repair and Genomic Instability
Open the complete 15-article guideHow Crosslink Repair Is Organised
When a replication fork stalls at an interstrand crosslink, the Fanconi anaemia core complex is recruited and monoubiquitinates the FANCD2-FANCI pair. This activated complex coordinates nucleases that unhook the crosslink and marks the site for downstream processing.
The resulting double-strand break is repaired by homologous recombination, which is why the pathway's downstream components overlap with the BRCA network. FANCD1 and FANCN are in fact BRCA2 and PALB2.
Fanconi Anaemia the Disease
Biallelic loss of a Fanconi anaemia gene causes the inherited syndrome: bone marrow failure, congenital anomalies, and a markedly raised risk of acute myeloid leukaemia and of squamous cell carcinomas of the head, neck and anogenital region.
Cells from affected individuals are hypersensitive to crosslinking agents such as mitomycin C and diepoxybutane, and this chromosome-breakage test remains a diagnostic assay.
What Pathway Membership Implies for a Tumour Report
A heterozygous pathogenic variant in a downstream gene such as BRCA2 or PALB2 carries well-defined cancer risk. For many upstream Fanconi genes, monoallelic cancer risk is uncertain or gene-specific and should not be assumed to match BRCA-level risk.
A tumour alteration in a Fanconi gene does not automatically equate to homologous recombination deficiency; functional or genomic-scar evidence is a separate measurement.
Crosslink Sensitivity and Therapy
The pathway's defining property — hypersensitivity to DNA crosslinking agents — is why platinum chemotherapy is particularly effective against Fanconi-deficient tumour cells, and why people with Fanconi anaemia tolerate standard-dose chemotherapy and radiotherapy poorly. Dose reductions and careful protocols are needed when treating cancers that arise in the syndrome.
Where a tumour has a BRCA2 or PALB2 alteration within this pathway, the treatment implications are those of homologous recombination deficiency: possible sensitivity to platinum and PARP inhibitors, judged on functional or genomic-scar evidence rather than on Fanconi-pathway membership alone.
Key Takeaways
- ·The Fanconi anaemia pathway repairs interstrand crosslinks and feeds into homologous recombination.
- ·Biallelic loss causes marrow failure and a high risk of leukaemia and squamous carcinomas.
- ·Risk from a single variant is gene-specific and is not uniformly BRCA-equivalent across the pathway.
Put these genes in pathway context
Frequently asked questions
Does a Fanconi-pathway gene alteration mean the tumour is HRD?
Not automatically. Downstream members such as BRCA2 and PALB2 do feed homologous recombination, but a tumour alteration in a Fanconi gene still needs separate functional or genomic-scar evidence to call homologous recombination deficiency.
Is single-variant cancer risk the same across the pathway?
No. Heterozygous BRCA2 or PALB2 variants carry well-defined risk; for many upstream Fanconi genes monoallelic risk is uncertain or gene-specific and should not be assumed to be BRCA-equivalent.
What does biallelic loss of a Fanconi gene cause?
Fanconi anaemia: bone-marrow failure, congenital anomalies, and a markedly raised risk of acute myeloid leukaemia and of squamous cell carcinomas of the head, neck and anogenital region.
References
- 1Fanconi anemia: current insights regarding epidemiology, cancer, and DNA repair. Hum Genet, 2022. PubMed
- 2The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance. Cell, 2024. PubMed
- 3Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancer. Breast Cancer Res, 2014. PubMed
Continue Reading
BRCA1 vs BRCA2: Different Roles in DNA Repair
2 min read
Chromothripsis: One Catastrophe, Many Rearrangements
3 min read
PALB2: DNA Repair, Inherited Risk and Tumour Findings
2 min read
Homologous Recombination Deficiency: BRCA, ATM and HRD Testing
6 min read
RECQ Helicases: Bloom, Werner and Genome Maintenance
3 min read
HRD Scores and Genomic Scars: What an HRD-Positive Result Means
3 min read
Choose your next research step
Move from this explanation into a gene profile, a pathway map, or the next evidence update.
BRCA1 has 100+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.